Th1 and Th2 cells in autoimmunity

Chemical Immunology

Volumn 63, Issue , 1996, Pages 158-171

  Druet, Philippe ^a   Sheela, Ramanathan ^a   Pelletier, Lucette ^a  

^a CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; CYTOKINE;

ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; AUTOIMMUNITY; B LYMPHOCYTE; DIABETES MELLITUS; HELPER CELL; LUPUS VULGARIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; UVEORETINITIS; ANIMAL; AUTOIMMUNE DISEASE; HUMAN; IMMUNOLOGY; PHYSIOLOGY; TH1 CELL; TH2 CELL;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; TH1 CELLS; TH2 CELLS;

EID: 0029988054     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319484     Document Type: Article

References (69)

1. Powrie E, Coffman RL: Cytokine regulation of T-cell function: Potential for therapeutic intervention. Immunol Today 1993,14:270-274.
2. Seder RA, Paul WE: Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu Rev Immunol 1994;12:635-673.
3. Fowell D, McKnight AJ, Powrie F, Dyke R, Mason D: Subsets of CD4+ T cells and their role in the induction and prevention of autoimmunity. Immunol Rev 1991;123:37-64.
4. Romagnani S Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994;12:227-257.
5. Hsieh C, Heimberger AB, Gold JS, O'Garra A, Murphy KM: Differential regulation of T helper phenotype development by interleukins 4 and 10 in an ab T-cell-receptor transgenic system. Proc Natl Acad Sci USA 1992;89:6065-6069.
6. D'Andrea A, Ma X, Aste-Amegaza M, Paganin C, Trinchieri G: Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: Priming for IL-12 and tumor necrosis factor a production. J Exp Med 1995;181;537-546.
7. Scott P, Pearce E, Cheever AW, Coffman RL, Sher A: Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev 1989;112 161-182
8. low subset. J Exp Med 1990,172:1701-1708.
9. Morrissey PH, Charrier K, Braddy S, Liggit D, Watson JD CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med 1993; 178:237-244.
10. hi CD4+ T cells Immunity 1994;1.553-582
11. Liblau RS, Singer SM, McDevitt HO: Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-38.
12. Kennedy MK, Torrance DS, Picha KS, Mohler KM: Analysis of cytokine mRNA expression in the central nervous system of mice with experimental allergic encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992;149:2496-2505.
13. Ando DG, Clayton J, Kono D, Urban JL, Sercarz EE: Encephalithogenic T cells in B10.PL model of experimental allergic encephlomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 1989;124:132-143.
14. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr: Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993;177:57-68.
15. Kuchroo VK, Prabhu MP, Brown JA, Ranger AM, Zamvill SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995;80:707-718.
16. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB: An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990;172:1193-1200.
17. Leonard JP, Waldburger KE, Goldman SJ: Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995,181:381-386.
18. MacPhee IAM, Antoni FN, Mason DW: Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. J Exp Med 1989;169:431-445.
19. Daynes DA, Araneo BA: Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and intereleukin 4. Eur J Immunol 1989;19:2319-2326.
20. Racke MK, Bonomo A, Scott DE, Canella B, Levine A, Raine CS, Shevach EM, Röcken M: Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease J Exp Med 1994;180:1961-1966.
21. Rott O, Fleischer B, Cash E: Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994;24:1434-1440.
22. Cash E, Minty A, Ferrara P, Caput D, Fradelizi D, Rott O: Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats J Immunol 1994;153:4258-4267.
23. Rott O, Cash E, Fleisher B: Phosphodiesterase inhibitor pentoxifylline. a selective suppressor of T helper type-1 but not type 2-associated lymphokine production prevents induction of experimental eacephalomyelitis in Lewis rats. Eur J Immunol 1993,23:1745-1775.
24. Racke MK, Burnett D, Pak S-H, Albert PS, Cannella B, Raine CS, McFarlin DE, Scott DE: Retinoid treatment of experimental allergic encephalomyelitis IL-4 correlates with improved disease course. J Immunol 1995;154:450-458.
25. Day MJ, Tse AGD, Puklavec M, Simmonds SJ, Mason DW: Targeting autoantigen to B cells prevents the induction of a cell-mediated autoimmune disease in rats. J Exp Med 1992;175:655-659.
26. Saoudi A, Simmonds S, Huitinga I, Mason D: Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: Evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigen-specific T cells. J Exp Med 1995;182:335-344
27. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by release of transforming growth factor β after antigen-specific triggering. Proc Natl Acad Sci USA 1992; 89:421-425.
28. Karpus WJ: CD4+ suppressor cells inhibit the function of effector cells of experimental autoimmune encephalomyelitis through a mechanism involving transforming growth factor-β J Immunol 1991; 146:1163-1168
29. Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner HL: Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
30. Le Gros G, Erard F: Non-cytotoxic, IL-4, IL-5, IL-10 producing CD8+ T cells: Their activation and effector functions. Curr Opin Immunol 1994;6:453-457.
31. Seder RA, Le Gros G: The functional role of CD8+ T helper type 2 cells. J Exp Med 1995;181: 5-7.
32. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, Annunziata N, Doetschman T: Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease Nature 1992;359:693-699.
33. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W: Interleukin-10-deficient mice develop chronic enterocolitis Cell 1993;75:263-274.
34. Savion S, Grover S, Kawano Y, Caspi RR: Uveitogenicity of T cell lines in the rat does not correlate with their production of TNF. INFγ or IL-3. Invest Ophthalmol Vis Sci 1992;33.932-935.
35. Saoudi A, Kuhn J, Huygen K, de Kozak Y, Velu T, Goldman M, Druet P, Bellon B: Th2 activated cells prevent experimental autoimmune uveoretinitis: A Th1-dependent autoimmune disease. Eur J Immunol 1993;23:3096-3103
36. Billiau A, Herremans H, Vandekerchkove F, Dijkmans R, Sobis H, Meulepas E, Carton H: Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma. J Immunol 1988;140:1506-1518.
37. Caspi RR, Chan C-C, Grubbs BG, Silver PB, Wiggert B, Parsa CF, Bahmanyar S, Billiau A, Heremans H: Endogenous systemic IFN-γ has a protective effect against ocular autoimmunity in mice. J Immunol 1994,152:890-899
38. Trembleau S, Penna G, Bosi E, Mortara A, Gately MK, Adorini L: Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med 1995; 181:817-821.
39. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA: Differential effects of anti-B7.1 and anti-B7.2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995,181:1145-1155.
40. Pennline KJ, Roque-Gaffney E, Monahan E: Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse Clin Immunol Immunopathol 1994;71:169-175.
41. Wogensen L, Lee M-S, Sarvetnick N: Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in non obese diabetic mice. J Exp Med 1994;179:1379-1384.
42. Moritani M, Yoshimoto K, Tashiro F, Hashimoto C, Miyazaki J, Li S, Kudo E, Iwahana H, Hayashi Y, Sano T, Itakura M: Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol 1994;6:927-1936.
43. Shehadeh N, Calcinaro F, Bradley BJ, Bruchlim I, Vardi P, Lafferty KJ: Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 1994;343:706-707
44. Williams RO, Feldmann M, Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine-collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-9788.
45. De Franco M, Gille-Perramant M-F, Mevel J-C, Couderc J: T helper subset involvement in two high antibody responder lines of mice (Biozzi mice): HI (susceptible) and HII (resistant) to collagen-induced arthritis. Eur J Immunol 1995;25:132-136
46. Romball CG, Weigle WO: Transfer of experimental autoimmune thyroiditis with T cell clones. J Immunol 1987;138:1092-1098.
47. Stull SJ, Sharp GC, Kyriakos M, Bickell JT, Braley-Mullen H: Induction of granulomatous experimental autoimmune thyroiditis in mice with in vitro activated effector T cells and anti-IFN-γ antibody. J Immunol 1992;149 2219-2226.
48. Braley-Mullen H, Sharp GC, Bickel JT, Kyriakos M: Induction of severe granulomatous experimental autoimmune thyroiditis in mice by effector cells activated in the presence of anti-interleukin 2 receptor antibody. J Exp Med 1991;173:899-912.
49. H2 cells in systemic autoimmunity: Insights from allogeneic diseases and chemically-induced autoimmumty Immunol Today 1991;12:223-227.
50. de Wit D, Van Mechelen M, Zanin C, Doutrelepont J-M, Velu T, Gérard C, Abramowicz D, Scheerlink J-P, De Baetselier P, Urbain J, Leo O, Goldman M, Moser M: Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol 1993;150 361-366.
51. Schurmans S, Heusser CH, Qin H, Merino J, Brighouse G, Lambert P. In vivo effects of anti-IL-4 monoclonal antibody on neonatal induction of tolerance and on an associated autoimmune syndrome. J Immunol 1990;145:2465-2473
52. Ulmland S, Razac S, Nahrebene K, Seymour B: Effects of in vivo administration of interferon (IFN)-γ, anti-IFNγ. or anti-interleukin-4 monoclonal antibodies in chronic autoimmune graft-versus-host disease. Clin Immunol Immunopathol 1992;63:66-73.
53. Via CS, Rus V, Gately MK, Finkelman FD: IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic autoimmune graft-versus-host disease. J Immunol 1994;153:4040-4047.
54. Florquin S, Goldman M. T cell subsets in glomerular diseases. Semin Immunopathol 1994;16: 71-80
55. 54a Saoudi A, Castedo M, Nochy D, Mandet C, Pasquier R, Druet P, Pelletier L: Self reactive anti-class II Th2 cell line derived from gold salt-injected rats trigger B cell polyclonal activation and transfer autoimmunity in CD8-depleted normal syngeneic recipients. Eur J Immunol 1995;25: 1972-1979.
56. 54b Prigent P, Saoudi A, Pannetier C, Graver P, Bonnefoy Y, Druet P, Hirsch F: Mercuric chloride, a chemical responsible for Th2-mediated autoimmunity in brown-norway rats, directly triggers T cells to produce IL-4. J Clin Invest 1995;96:1484-1489.
57. Jacob C, van der Meide P, McDevitt H: In vivo treatment of (NZB × NZW) mice with monoclonal antibody to γ-interferon. J Exp Med 1987;166:798-802.
58. Ozmen L, Roman D, Fountoulakis M, Schmid G, Ryffel B, Garotta G: Experimental therapy of systemic lupus erythematosus: The treatment of NZB/W mice with soluble interferon-γ receptor inhibits the onset of glomerulonephritis Eur J Immunol 1995;25:6-12.
59. Diaz Gallo C, Jevnikar A, Brennan D, Florquin S, Pacheco-Silva A, Rubin Kelley V: Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney Int 1992;42:851-859.
60. Finck BK, Chan B, Wofsy D: Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994;94:585-591.
61. Ishida H, Muchamuel T, Sakaguchi S, Menon S, Howard M: Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W mice. J Exp Med 1994;179: 305-310.
62. Fossati L, Takahashi S, Merino R, Iwamoto M, Aubry J-P, Nose C, Spach R, Motta R, Izui S: An MRL/MpJ-lpr/lpr substrain with a limited expansion of lpr double-negative T cells and a reduced autoimmune syndrome. Int Immunol 1993;5:525-532
63. Del Prete G, Maggi E, Pizzolo G, Romagnani S: CD30, Th2 cytokines and HIV infection: A complex and fascinating link. Immunol Today 1995;16:76-80.
64. Nagafuchi H, Suzuki N, Mizuchima Y, Sakana T. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus J Immunol 1993;151:6525-6534.
65. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet J-C, Alarcon-Segovia D, Galanaud P, Emilie D: Role of interleukin-10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus J Exp Med 1995,181:839-844.
66. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner H, Hafler DA: Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994;179:973-984.
67. Panitch HS, Hirsch RL, Schindler J, Johnson KP: Treatment of multiple sclerosis with γ interferon: Exacerbations associated with activation of the immune system. Neurology 1987;37:1097-1102
68. Elliott MJ, Maini RN, Feldmann M, Fox-Long A, Charles P, Katsikis P, Brennan M, Walker J, Bijl H, Ghrayeb J, Woody J: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNFα, safety, clinical efficacy and regulation of acute phase response. Arthritis Rheum 1993; 36:1681-1686.
69. Cope AP, Londei M, Chu NR, Cohen SBA, Elliott MJ, Brennan FM, Maini RN, Feldmann M: Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: Reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis patients. J Clin Invest 1994;94:749-760.